Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

428 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
The real-world effectiveness of anti-RANKL antibody denosumab on the clinical fracture prevention in patients with rheumatoid arthritis: The ANSWER cohort study.
Murata K, Uozumi R, Hashimoto M, Ebina K, Akashi K, Onishi A, Nagai K, Yoshikawa A, Katayama M, Son Y, Amuro H, Hara R, Yamamoto W, Watanabe R, Murakami K, Tanaka M, Ito H, Morinobu A, Matsuda S. Murata K, et al. Among authors: onishi a. Mod Rheumatol. 2022 Jul 1;32(4):834-838. doi: 10.1093/mr/roab043. Mod Rheumatol. 2022. PMID: 34910199
Mycophenolate mofetil versus intravenous cyclophosphamide for induction treatment of proliferative lupus nephritis in a Japanese population: a retrospective study.
Onishi A, Sugiyama D, Tsuji G, Nakazawa T, Kogata Y, Tsuda K, Naka I, Nishimura K, Misaki K, Kurimoto C, Hayashi H, Kageyama G, Saegusa J, Sugimoto T, Kawano S, Kumagai S, Morinobu A. Onishi A, et al. Mod Rheumatol. 2013 Jan;23(1):89-96. doi: 10.1007/s10165-012-0634-9. Epub 2012 Mar 25. Mod Rheumatol. 2013. PMID: 22447557
Drug tolerability and reasons for discontinuation of seven biologics in 4466 treatment courses of rheumatoid arthritis-the ANSWER cohort study.
Ebina K, Hashimoto M, Yamamoto W, Hirano T, Hara R, Katayama M, Onishi A, Nagai K, Son Y, Amuro H, Yamamoto K, Maeda Y, Murata K, Jinno S, Takeuchi T, Hirao M, Kumanogoh A, Yoshikawa H. Ebina K, et al. Among authors: onishi a. Arthritis Res Ther. 2019 Apr 11;21(1):91. doi: 10.1186/s13075-019-1880-4. Arthritis Res Ther. 2019. PMID: 30971306 Free PMC article.
Correction to: Drug tolerability and reasons for discontinuation of seven biologics in 4466 treatment courses of rheumatoid arthritis-the ANSWER cohort study.
Ebina K, Hashimoto M, Yamamoto W, Hirano T, Hara R, Katayama M, Onishi A, Nagai K, Son Y, Amuro H, Yamamoto K, Maeda Y, Murata K, Jinno S, Takeuchi T, Hirao M, Kumanogoh A, Yoshikawa H. Ebina K, et al. Among authors: onishi a. Arthritis Res Ther. 2019 May 6;21(1):114. doi: 10.1186/s13075-019-1897-8. Arthritis Res Ther. 2019. PMID: 31060597 Free PMC article.
Drug tolerability and reasons for discontinuation of seven biologics in elderly patients with rheumatoid arthritis -The ANSWER cohort study.
Ebina K, Hashimoto M, Yamamoto W, Hirano T, Hara R, Katayama M, Onishi A, Nagai K, Son Y, Amuro H, Yamamoto K, Maeda Y, Murata K, Jinno S, Takeuchi T, Hirao M, Kumanogoh A, Yoshikawa H. Ebina K, et al. Among authors: onishi a. PLoS One. 2019 May 8;14(5):e0216624. doi: 10.1371/journal.pone.0216624. eCollection 2019. PLoS One. 2019. PMID: 31067271 Free PMC article.
428 results